Skip to main content

From the Helm: CSL’s David Lamont on the biotech giant’s bright future

Jessica Amir
February 20, 2020

In the latest instalment of Bell Direct’s From the Helm series, Jess has a chat with CSL’s CFO David Lamont.

David gives the inside scoop on CSL, the market leader in the blood plasma and vaccine market. Additionally, he explains CSL’s own products, programmes and partnerships, and the steps taken by the medical giant to tackle coronavirus.

Plus, he sheds some light on the unique situation the broader pharmaceuticals industry finds itself in when it comes to new competition, as well as CSL’s future proofing strategy.

Closing Bell 2 February

Grady Wulff
February 3, 2023

Morning Bell 2 February

Grady Wulff
February 2, 2023

Closing Bell 1 February

Grady Wulff
February 1, 2023

Morning Bell 1 February

Grady Wulff
February 1, 2023

Closing Bell 31 January

Grady Wulff
February 1, 2023

Morning Bell 31 January

Sophia Mavridis
January 31, 2023

Closing Bell 30 January

Grady Wulff
January 30, 2023

Morning Bell 30 January

Grady Wulff
January 30, 2023

Closing Bell 25 January

Grady Wulff
January 25, 2023

Morning Bell 25 January

Grady Wulff
January 25, 2023

Closing Bell 24 January

Grady Wulff
January 24, 2023

Morning Bell 24 January

Grady Wulff
January 24, 2023